- Latest available (Revised)
- Original (As adopted by EU)
Commission Regulation (EU) No 544/2011 of 10 June 2011 implementing Regulation (EC) No 1107/2009 of the European Parliament and of the Council as regards the data requirements for active substances (Text with EEA relevance) (repealed)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
There are currently no known outstanding effects for the Commission Regulation (EU) No 544/2011 (repealed).
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Article 1.The data requirements for the approval of an active substance...
Article 2.This Regulation shall enter into force on the 20th day...
1. Identity of the active substance
1.2. Manufacturer (name, address, including location of plant)
1.4.1 In point 1.4, “ the GB mandatory classification and labelling...
1.8. Method of manufacture (synthesis pathway) of the active substance
1.9. Specification of purity of the active substance in g/kg
1.10. Identity of isomers, impurities and additives (e.g. stabilisers), together with...
2. Physical and chemical properties of the active substance
(i) The information provided, must describe the physical and chemical properties...
(ii) The information provided, taken together with that provided for relevant...
(iii) The extent to which active substances of which approval is...
(iv) In certain specified instances, tests must be conducted using purified...
2.3. Vapour pressure (in Pa), volatility (e.g. Henry’s law constant)
2.4. Appearance (physical state, colour and odour; if known)
2.5. Spectra (UV/VIS, IR, NMR, MS), molecular extinction at relevant wavelengths...
2.6. Solubility in water including effect of pH (4 to 10)...
2.8. Partition coefficient n-octanol/water including effect of pH (4 to 10)...
2.9. Stability in water, hydrolysis rate, photochemical degradation, quantum yield and...
2.9.1. The hydrolysis rate of purified active substances (usually radiolabelled active...
2.9.2. For compounds with a molar (decadic) absorption coefficient (ε) > 10...
2.9.3. Where necessary to investigate direct phototrans-formation, the quantum yield of...
2.9.4. Where dissociation in water occurs, the dissociation constant(s) (pKa values)...
2.10. Stability in air, photochemical degradation, identity of breakdown product(s)
3. Further information on the active substance
(i) The information provided must describe the intended purposes for which...
(ii) The information provided must specify the normal methods and precautions...
(iii) The studies, data and information submitted, together with other relevant...
(iv) The studies, data and information submitted, together with other relevant...
(v) The information and data referred to are required for all...
3.1. Function, e.g. fungicide, herbicide, insecticide, repellent, growth regulator
3.2. Effects on harmful organisms, e.g. contact poison, inhalation poison, stomach...
3.3. Field of use envisaged, e.g. field, protected crops, storage of...
3.4. Harmful organisms controlled and crops or products protected or treated...
3.6. Information on the occurrence or possible occurrence of the development...
3.7. Recommended methods and precautions concerning handling, storage, transport or fire...
4.1. Methods for the analysis of the active substance as manufactured...
4.1.1. Methods, which must be described in full, must be provided...
4.1.2. Methods must also be provided for the determination of significant...
4.1.3. Specificity, linearity, accuracy and repeatability
4.1.3.1. Specificity of methods submitted must be demonstrated and reported. In...
4.1.3.2. The linearity of proposed methods over an appropriate range must...
4.1.3.3. Accuracy is required for methods for the determination of pure...
4.1.3.4. For the repeatability in the determination of the pure active...
5. Toxicological and metabolism studies
(i) The information provided, taken together with that provided for one...
(ii) There is a need to investigate and report all potentially...
(iii) In the context of the influence that impurities can have...
(iv) Where studies are conducted using an active substance produced in...
(vi) For all studies actual achieved dose in mg/kg body weight,...
(vii) Where, as a result of metabolism or other processes in...
(viii) The way of administration of the test substance depends on...
5.1. Studies on absorption, distribution, excretion and metabolism in mammals
5.9.1. Medicinal surveillance on manufacturing plant personnel
5.9.2. Direct observation, e.g. clinical cases and poisoning incidents
5.9.3. Observations on exposure of the general population and epidemiological studies...
5.9.4. Diagnosis of poisoning (determination of active substance, metabolites), specific signs...
5.9.5. Proposed treatment: first aid measures, antidotes, medical treatment
6. Residues in or on treated products, food and feed
(i) The information provided, taken together with that provided for one...
(ii) A detailed description (specification) of the material used, as provided...
(iii) Studies shall be performed in accordance with guidance issued under...
(iv) Where relevant, data shall be analysed using appropriate statistical methods....
6.1. Metabolism, distribution and expression of residue in plants
6.2. Metabolism, distribution and expression of residue in livestock
6.5. Effects of industrial processing and/or household preparations
6.7. Proposed maximum residue levels (MRLs) and residue definition
6.8. Proposed pre-harvest intervals for envisaged uses, or withholding periods or...
6.9. Estimation of the potential and actual exposure through diet and...
7. Fate and behaviour in the environment
(i) The information provided, taken together with that for one or...
(ii) In particular, the information provided for the active substance, together...
(iii) A detailed description (specification) of the material used, as provided...
(iv) Where radio-labelled test material is used, radio-labels shall be positioned...
(v) It may be necessary to conduct separate studies for metabolites,...
(vi) Where relevant, tests shall be designed and data analysed using...
(i) The information provided, taken together with that for one or...
(ii) In particular, the information provided for the active substance, together...
(iii) There is a need to report all potentially adverse effects...
(iv) The information on fate and behaviour in the environment, generated...
(v) Where relevant, tests shall be designed and data analysed using...
(vi) A detailed description (specification) of the material used, as provided...
(vii) Where studies are conducted using active substance produced in the...
(viii) In the case of studies in which dosing extends over...
(ix) For all feeding studies, average achieved dose must be reported,...
(x) It may be necessary to conduct separate studies for metabolites,...
8.2. Effects on aquatic organisms
8.6. Effects on other non-target organisms (flora and fauna) believed to...
10. Proposals including justification for the proposals for the classification and...
PART B MICRO-ORGANISMS INCLUDING VIRUSES
(i) Active substances are defined in Article 2(2) of Regulation (EC)...
(ii) For all micro-organisms that are subject to application all available...
(iii) Pending the acceptance of specific guidelines at international level, the...
(iv) Where testing is done, a detailed description (specification) of the...
(v) Where the micro-organism has been genetically modified, a copy of...
(vi) Where relevant, data shall be analysed using appropriate statistical methods....
(vii) In the case of studies in which dosing extends over...
1. Identity of the micro-organism
1.3. Name and species description, strain characterisation
(i) The micro-organism should be deposited at an internationally recognised culture...
(ii) Each micro-organism that is subject to the application shall be...
(iii) Best available technology should be used to identify and characterise...
(iv) Common name or alternative and superseded names and code names...
1.4. Specification of the material used for manufacturing of formulated products...
3. Further information on the micro-organism
(i) The information provided must describe the intended purposes for which...
(ii) The information provided must specify the normal methods and precautions...
(iii) The studies, data and information submitted, must demonstrate the suitability...
(iv) The information and data referred to are required for each...
3.5. Information on the occurrence or possible occurrence of the development...
3.6. Methods to prevent loss of virulence of seed stock of...
3.7. Recommended methods and precautions concerning handling, storage, transport or fire...
(i) Available information based on the properties of the micro-organism and...
(ii) The information provided, taken together with that provided for one...
(iii) All effects found during investigations shall be reported. Investigations which...
(iv) For all studies actual achieved dose in colony forming units...
(v) Evaluation of the micro-organism shall be carried out in a...
5.6. Summary of mammalian toxicity, pathogenicity and infectiveness and overall evaluation...
7. Fate and behaviour in the environment
(i) Information on the origin, the properties, and the survival of...
(ii) The information provided, taken together with other relevant information, and...
(iii) In particular, the information provided shall be sufficient to:
(iv) Any relevant metabolites (i.e. of concern for human health and/or...
(v) Available information on the relationship with naturally occurring wild type...
(vi) Before performing studies as referred to below, the applicant shall...
8. Effects on non-target organisms
(i) The information on identity, biological properties and further information in...
(ii) The choice of the appropriate non-target organisms for testing of...
(iii) The information provided, taken together with that for one or...
(iv) In particular, the information provided for the micro-organism, together with...
(v) There is a need to report all potentially adverse effects...
(vi) For all studies, average achieved dose in cfu/kg body weight...
(vii) It may be necessary to conduct separate studies for relevant...
(viii) In order to facilitate the assessment of the significance of...
(ix) Tests must be performed unless it can be justified that...
The Whole Regulation you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: